Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership

Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval

Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy

Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials

Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###

Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies

Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization

biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.

Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions

Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.

Why do CRISPR/Cas9 gene editing therapies fail after showing efficacy in rodent models

CRISPR/Cas9 gene editing therapies often show promising results in rodent models but can encounter several challenges when translated to human clinical settings, leading to failures or reduced efficacy. These challenges include differences in biology between species, immune responses, off-target effects, and delivery mechanisms. Differences in Biology Between Species Rodent models, such as mice, are extensively […]